ArticleJournal of ginseng research2026
Ginsenoside Rg5 mitigates tenocyte death
Article in Journal of ginseng research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ginsenosides Rh2 and Rg3 in first-line combination therapy: Prospects for rapid clinical translation in drug-resistant triple-negative breast cancer.Journal of ginseng research · 2026Review
- Ginsenosides fromJournal of ginseng research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: The current study aimed to investigate the effects of the ginsenoside Rg5 (Rg5) on aging-induced apoptosis and ferroptosis in tenocytes and explore its mechanism of action. Methods: The expression of various proteins related to this study was assessed Results: Rg5 treatment attenuated apoptosis, ferroptosis, ER stress, and oxidative stress in D-galactose-treated tenocytes. Moreover, it mitigated ECM degradation and enhanced cell migration in tenocytes in the presence of D-galactose. Rg5 treatment dose-dependently increased SIRT6 expression and the levels of autophagy markers, such as those associated with LC3 conversion and p62 degradation. siRNA-mediated suppression of SIRT6 or 3-MA, an autophagy inhibitor, reduced the effects of Rg5 on D-galactose-treated tenocytes. Rg5 administration improved tissue damage as well as ER stress and ferroptosis markers in the Achilles tendons of mouse models established by local injection of D-galactose and collagenase type I. In addition to the Conclusion: These results suggest that Rg5 attenuates ER stress and oxidative stress through the SIRT6/autophagy axis, thereby mitigating ferroptosis and apoptosis in aging-conditioned tenocytes. The present study sheds light on a novel therapeutic strategy for aging-mediated tendinopathy involving the use of Rg5.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.